MA47111A - Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer - Google Patents
Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancerInfo
- Publication number
- MA47111A MA47111A MA047111A MA47111A MA47111A MA 47111 A MA47111 A MA 47111A MA 047111 A MA047111 A MA 047111A MA 47111 A MA47111 A MA 47111A MA 47111 A MA47111 A MA 47111A
- Authority
- MA
- Morocco
- Prior art keywords
- sirpgamma
- cancer
- treatment
- targeting agents
- targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662438227P | 2016-12-22 | 2016-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47111A true MA47111A (fr) | 2019-10-30 |
Family
ID=61022415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047111A MA47111A (fr) | 2016-12-22 | 2017-12-19 | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230139592A1 (fr) |
EP (1) | EP3559037A1 (fr) |
MA (1) | MA47111A (fr) |
WO (1) | WO2018118887A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
EP3843772A2 (fr) * | 2018-08-31 | 2021-07-07 | ALX Oncology Inc. | Polypeptides leurres |
US20220305081A1 (en) * | 2019-06-24 | 2022-09-29 | Amgen Inc. | Inhibitions of sirp-gamma for cancer treatment |
CA3237787A1 (fr) * | 2021-11-10 | 2023-05-19 | Sandip PANICKER | Anticorps sirp gamma et leurs utilisations |
CN114085869A (zh) * | 2021-11-19 | 2022-02-25 | 许川 | 一种特异性表达人源性sirpg的转基因小鼠的构建方法及其应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US510997A (en) | 1893-12-19 | Water-closet | ||
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4311688A (en) | 1979-10-29 | 1982-01-19 | Serono Laboratories Inc. | Composition and method for cancer detection in humans |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5103098A (en) | 1989-11-09 | 1992-04-07 | Board Of Regents, The University Of Texas System | High resolution gamma ray detectors for positron emission tomography (pet) and single photon emission computed tomography (spect) |
US5210421A (en) | 1991-06-10 | 1993-05-11 | Picker International, Inc. | Simultaneous transmission and emission converging tomography |
US5208581A (en) | 1991-11-22 | 1993-05-04 | General Electric Company | High speed communication apparatus for computerized axial tomography (cat) scanners with matching receiver |
US6193969B1 (en) | 1993-06-03 | 2001-02-27 | Protherics Inc. | Antibody fragments in therapy |
US5446799A (en) | 1993-11-01 | 1995-08-29 | Picker International, Inc. | CT Scanner with improved processing efficiency 180 degrees+ fan angle reconstruction system |
US5406479A (en) | 1993-12-20 | 1995-04-11 | Imatron, Inc. | Method for rebinning and for correcting cone beam error in a fan beam computed tomographic scanner system |
US5600145A (en) | 1995-01-19 | 1997-02-04 | Picker International, Inc. | Emission/transmission device for use with a dual head nuclear medicine gamma camera with the transmission source located behind the emission collimator |
US5608221A (en) | 1995-06-09 | 1997-03-04 | Adac Laboratories | Multi-head nuclear medicine camera for dual SPECT and PET imaging with monuniform attenuation correction |
SE9602594D0 (sv) | 1996-07-01 | 1996-07-01 | Stefan Nilsson | Förfarande och anordning vid datortomografi |
US5841140A (en) | 1997-01-08 | 1998-11-24 | Smv America, Inc. | Gamma camera for pet and spect studies |
US5946371A (en) | 1997-12-08 | 1999-08-31 | Analogic Corporation | Method and apparatus for volumetric computed tomography scanning with offset symmetric or asymmetric detector system |
US6115446A (en) | 1999-04-09 | 2000-09-05 | Arch Development Corp. | Fast reconstruction of fan-beam CT and SPECT |
US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
WO2006110728A2 (fr) | 2005-04-12 | 2006-10-19 | The Uab Research Foundation | Agregats de tegument immunogenes |
EP3753947A1 (fr) | 2007-09-14 | 2020-12-23 | Adimab, LLC | Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US7973019B1 (en) | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
WO2010037134A2 (fr) * | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Carcinogenese de cellules souches multietapes |
CN103282560B (zh) | 2010-07-16 | 2016-08-03 | 阿迪马布有限责任公司 | 抗体文库 |
US20130331297A1 (en) | 2010-07-16 | 2013-12-12 | Avantgen, Inc. | Novel peptides and uses thereof |
WO2014100490A1 (fr) | 2012-12-19 | 2014-06-26 | Adimab, Llc | Analogues d'anticorps multivalents, et leurs procédés de préparation et d'utilisation |
JP6606505B2 (ja) * | 2014-03-11 | 2019-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗SIRPα抗体および二重特異性マクロファージ増強抗体 |
GB201408100D0 (en) * | 2014-05-07 | 2014-06-18 | Sec Dep For Health The | Detection method |
AU2015329696A1 (en) * | 2014-10-10 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to eliminate cancer stem cells by targeting CD47 |
PT3298043T (pt) * | 2015-05-18 | 2021-03-08 | Ab Initio Biotherapeutics Inc | Composições de polipéptido sirp e métodos de utilização |
US10946042B2 (en) * | 2015-12-01 | 2021-03-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for selective phagocytosis of human cancer cells |
-
2017
- 2017-12-19 US US16/470,719 patent/US20230139592A1/en active Pending
- 2017-12-19 MA MA047111A patent/MA47111A/fr unknown
- 2017-12-19 EP EP17833041.1A patent/EP3559037A1/fr not_active Withdrawn
- 2017-12-19 WO PCT/US2017/067257 patent/WO2018118887A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20230139592A1 (en) | 2023-05-04 |
EP3559037A1 (fr) | 2019-10-30 |
WO2018118887A1 (fr) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45192A (fr) | Traitement d'association | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
DK3706796T3 (da) | Eksosomerer som RNA terapeutikske midler | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
MA45073A (fr) | Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers | |
MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA46608A (fr) | Formulation liposomale destinée à être utilisée dans le traitement du cancer | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
MA41794A (fr) | Agents thérapeutiques modifiés et compositions associées | |
MA53506A (fr) | Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules | |
MA46361A (fr) | Traitement du cancer de la prostate | |
MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
MA47408A (fr) | Traitement du cancer | |
MA46062A (fr) | Traitement par ascaroside de l'oesophagite à éosinophiles | |
DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
MA45046A (fr) | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules | |
DK3400072T3 (da) | Formuleringer til behandling af blærecancer |